Skip to main content

Signed · France · Pharma and biotech

Revvity agrees to acquire Human Cell Design.

Revvity, based in Waltham, Massachusetts, signed a definitive agreement on 9 September 2026 to acquire Human Cell Design, a Toulouse, France, biotechnology company that makes human cell models for diabetes, obesity and other metabolic disease research. It was signed on 9 September 2026. It had not completed by 28 October 2026.

SigningDay 100

Signing 9 September 2026

Buyer
Revvity, Inc. ·Waltham, United States
Target
Human Cell Design ·Toulouse, France
Type
Acquisition
Announced
9 September 2026
Signed
9 September 2026
Value
Not disclosed
People
Not stated in the release
Last checked
28 October 2026

The people side in France

Get the briefing

Deals into Europe lists public facts with their sources, checked every working day by Octagon Professionals International. Corrections go to info@octagon.nl and are made within one working day. How we track deals.

Enabling organisations to operate across borders with clarity, compliance, and trust.

All deals into Europe